Articles related to GLP-1 RECEPTOR AGONISTS

Older adults with diabetes and frailty frequently experience overtreatment despite individualized glycemic goals that prioritize safety over intensive control. A narrative review highlights deprescribing strategies, relaxed glycemic targets, and medication adjustments intended to reduce hypoglycemia, falls, and treatment burden.

Adults with type 2 diabetes initiating GLP-1 receptor agonists experienced higher rates of nonscarring alopecia than matched users of SGLT-2 or DPP-4 inhibitors. The association persisted across multiple analyses, though absolute risk remained low.

Online claims linking GLP-1 receptor agonists to increased penis size continue attracting patient attention. Available evidence suggests perceived changes may reflect weight loss and erectile function changes rather than anatomic growth.

The ACC updated its expert consensus pathway for HFpEF, emphasizing diagnostic scoring, comorbidity assessment, and newer cardiometabolic therapies. The pathway reflects emerging evidence while remaining aligned with existing heart failure guidelines.

A Swedish register-based cohort associated GLP-1 receptor agonist use with higher relative risk of anterior ischemic optic neuropathy. Absolute event rates were low, and findings attenuated after diabetes-severity controls.

Medicare’s new GLP-1 Bridge Program expands lower-cost access to certain weight-loss medications for eligible beneficiaries. Concurrent ISMP guidance outlines common medication errors and counseling challenges as more patients initiate GLP-1 therapy.